IPCS INCHEM Home

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

LYNOESTRENOL

For definition of Groups, see Preamble Evaluation.

VOL.: 21 (1979) (p. 407)

5. Summary of Data Reported and Evaluation

(N.B. - This section should be read in conjunction with the General Remarks on Sex Hormones and with the General Conclusions on Sex Hormones.)

5.1 Experimental data

Lynoestrenol was tested by oral administration in mice and rats, alone or in combination with mestranol. It did not increase the incidence of tumours.

5.2 Human data

No case reports or epidemiological studies on lynoestrenol alone were available to the Working Group. Epidemiological studies on steroid hormones used in oestrogen-progestin oral contraceptive preparations have been summarized in the section, 'Oestrogens and Progestins in Relation to Human Cancer'.

5.3 Evaluation

No evaluation of the carcinogenicity of lynoestrenol could be made. In humans, oral contraceptives containing oestrogens in combination with progestins have been related causally to an increased incidence of benign liver adenomas and a decreased incidence of benign breast disease.

Subsequent evaluation: Suppl. 7 (1987) (Progestins; combined oral contraceptives)


Last updated: 7 April 1998






















    See Also:
       Toxicological Abbreviations